What question did this study set out to answer?

To evaluate the Advanced Lung Cancer Inflammation Index (ALI) as a prognostic tool in patients with unresectable hepatocellular carcinoma (u-HCC).

March 23, 2026Hepatology Research1 citations

View Full Paper

The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy

VNVăn Đức NguyễnUniversity of the Pacific KMKosuke MatsuiKansai Medical University HKHisashi KosakaKansai Medical University

Key Points

To evaluate the Advanced Lung Cancer Inflammation Index (ALI) as a prognostic tool in patients with unresectable hepatocellular carcinoma (u-HCC).
Retrospective analysis of u-HCC patients receiving Atezolizumab and Bevacizumab therapy
Assessment of pretreatment ALI values and their association with survival and disease control
High pretreatment ALI values associated with improved survival rates
Increased disease control observed in patients with high ALI
Potential utility of ALI as a prognostic marker in clinical management

Abstract

A high pretreatment ALI value was associated with improved survival and disease control in u-HCC patients receiving Atez/Bev, underscoring its potential utility as a prognostic marker for clinical management and further studies.

AI에게 질문

Bookmark

View Full Paper

AI에게 질문

Bookmark

View Full Paper

The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy

Key Points

Abstract

Cite This Study